EUVIMEDEUVIMED entdecken
Open Access

Reprogramming oncogenic mitochondria in pancreatic adenocarcinoma through BRD4 inhibition leads to programmed cell death

Chun Cai, Michael W Spinrad, Lauren C Gattie, Rui Wang, Mohammad Amir Afjal, Jun Yang, Nour Yadak, David Shibata, Wei Li, Amandeep Bajwa, Evan S Glazer

The Journal of Pharmacology and Experimental Therapeutics · 2025

DOI: 10.1016/j.jpet.2025.103751 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2025. Verfasst von Chun Cai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The University of Tennessee Health Science Center, Memphis, Tennessee; Center for Cancer Research, The University of Tennessee…. Hauptthemen laut MEDLINE: Transcription Factors, Pancreatic Neoplasms, Mitochondria, Cell Cycle Proteins. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIDDK NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDA) is an almost universally fatal disease. Recent advances in the understanding of PDA bioenergetic dynamic equilibrium have illuminated a potential therapeutic target in bromodomain-related protein 4 (BRD4), the most active member of the bromo- and extraterminal domain (BET) protein family of transcription factors. We previously demonstrated that BET inhibitors (BETi) decrease PDA cell proliferation and enhance chemosensitivity. We hypothesized that BETi activates mitophagy and ferroptosis in PDA. Using pharmacological and genetic BRD4 inhibition in PDA patient-derived models, we investigated the effects of BETi on mitochondrial function, mitochondrial protein complex production, ATP production, cellular respiration, autophagy/mitophagy, and murine tumor growth with BMS-986158, a BETi. We determined the role of BRD4 in PDA by evaluating mitophagy and autophagy. In PDA models, we found that BETi decreased cellular respiration (P < .01), decreased ATP production (P < .001), and increased intracellular iron uptake (P < .01) while inducing mitophagy through dysregulated mitochondria complex protein levels. Murine PDA tumors grew slower and were smaller when treated with BETi compared with the control treatment. PDA tumors from experimentally treated mice contained more lipid vacuoles than those from the vehicle control group (P < .01), consistent with ferroptosis. BETi therapy decreased isocitrate dehydrogenase-1 expression, indicating increased chemosensitivity. BETi dysregulate mitochondrial complexes inducing mitophagy. BETi is a promising therapeutic strategy for attacking oncogenic mitochondrial behavior in PDA. We demonstrated a series of mitochondrial-centered events in a temporal sequence leading to cell death. This treatment controls tumors and increases chemosensitivity, offering a novel therapeutic strategy. SIGNIFICANCE STATEMENT: Bromo- and extraterminal domain inhibition is a novel therapeutic strategy for attacking oncogenic mitochondrial behavior in pancreatic ductal adenocarcinoma. Using this strategy in patient-derived models, this study demonstrated a series of mitochondrial-centered events in a temporal sequence leading to cell death and tumor control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcription FactorsPancreatic NeoplasmsMitochondriaCell Cycle ProteinsApoptosisCarcinoma, Pancreatic DuctalAdenocarcinomaAnimalsHumansMiceCell Line, TumorMitophagyAutophagyBromodomain Containing Proteins

Stichwörter der Autor:innen

Bromo- and extraterminal domainCancer therapeuticsMitochondrial stressMitophagyPancreatic ductal adenocarcinoma

Substanzen

Transcription FactorsBRD4 protein, humanCell Cycle ProteinsBromodomain Containing Proteins

Autor:innen und Institutionen

  • Department of Surgery, The University of Tennessee Health Science Center, Memphis, Tennessee; Center for Cancer Research, The University of Tennessee Health Science Center, Memphis, Tennessee.
  • Department of Surgery, The University of Tennessee Health Science Center, Memphis, Tennessee.
  • Department of Pharmaceutical Sciences, The University of Tennessee Health Science Center, Memphis, Tennessee.
  • Transplant Research Institute, Department of Surgery, The University of Tennessee Health Science Center, Memphis, Tennessee.
  • Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee; Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, Tennessee; St. Jude Graduate School of Biomedical Sciences,…
  • Department of Pathology, The University of Tennessee Health Science Center, Memphis, Tennessee.

Förderung

  • NCI NIH HHS
  • NIDDK NIH HHS
  • National Institutes of Health
  • Center for Cancer Research
  • National Institutes of Health National Cancer Institute

Zitieren

APA

Cai, C., Spinrad, M. W., Gattie, L. C., Wang, R., Afjal, M. A., Yang, J., Yadak, N., Shibata, D., Li, W., Bajwa, A., & Glazer, E. S. (2025). Reprogramming oncogenic mitochondria in pancreatic adenocarcinoma through BRD4 inhibition leads to programmed cell death. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/j.jpet.2025.103751

Vancouver

Cai C, Spinrad MW, Gattie LC, Wang R, Afjal MA, Yang J, et al. Reprogramming oncogenic mitochondria in pancreatic adenocarcinoma through BRD4 inhibition leads to programmed cell death. The Journal of Pharmacology and Experimental Therapeutics. 2025. doi:10.1016/j.jpet.2025.103751

BibTeX
@article{Cai2025,
  author = {Cai, Chun and Spinrad, Michael W and Gattie, Lauren C and Wang, Rui and Afjal, Mohammad Amir and Yang, Jun and Yadak, Nour and Shibata, David and Li, Wei and Bajwa, Amandeep and Glazer, Evan S},
  title = {Reprogramming oncogenic mitochondria in pancreatic adenocarcinoma through BRD4 inhibition leads to programmed cell death},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2025},
  doi = {10.1016/j.jpet.2025.103751}
}
Kostenlos starten →